ZW-191 is an antibody-drug conjugate (ADC) targeting folate receptor α (FRα). ZW-191 consists of ZW-191 Antibody as the antibody component and MC-GGFG-AM-(10Me-11F-Camptothecin) as the linker-payload component. ZW-191 possesses excellent tumor sphere penetration, cellular internalization and payload delivery capabilities, and can release a topoisomerase 1 inhibitor inside tumor cells to inhibit tumor cell activity. ZW-191 exerts a potent bystander effect on both antigen-positive and antigen-negative cells. ZW-191 exhibits prominent activity in xenograft models of cell lines with different FRα expression levels. ZW-191 can be used in studies related to ovarian cancer, non-small cell lung cancer, endometrial cancer and triple-negative breast cancer [1] [2].
In Vivo, ZW-191 exerts potent antitumor activity in cell line-derived xenograft and patient-derived xenograft models covering different FRα expression levels. ZW-191 maintains favorable tolerability in rodents after two administrations at a dose of 200 mg/kg. ZW-191 exhibits satisfactory safety profiles in non-human primates when given twice at a dose of 30 mg/kg. ZW-191 displays optimal pharmacokinetic characteristics in rodents and non-human primates during in vivo assessments[1].
In Vitro, ZW-191 shows detectable apparent binding affinity in FRα-expressing cells. ZW-191 mediates superior cellular internalization and payload delivery compared with other FRα-targeted antibodies applied in different ADCs[1]. ZW191 demonstrates strong FRα binding, superior tumor spheroid penetration, cellular internalization, and cytotoxic activity in FRα-expressing cancer cells[1][2].
References:
[1]. Lawn S, et al. Abstract 2641: ZW191, a novel FRa-targeting antibody drug conjugate bearing a topoisomerase 1 inhibitor payload. Cancer Research. 2023;83(7_Supplement):2641.
[2]. Lawn S, et al. Abstract 1862: ZW191 - a FRα-targeting antibody drug conjugate with strong preclinical activity across multiple FRα-expressing indications. Cancer Research. 2024;84(6_Supplement):1862.
In Vivo, ZW-191 exerts potent antitumor activity in cell line-derived xenograft and patient-derived xenograft models covering different FRα expression levels. ZW-191 maintains favorable tolerability in rodents after two administrations at a dose of 200 mg/kg. ZW-191 exhibits satisfactory safety profiles in non-human primates when given twice at a dose of 30 mg/kg. ZW-191 displays optimal pharmacokinetic characteristics in rodents and non-human primates during in vivo assessments[1].
In Vitro, ZW-191 shows detectable apparent binding affinity in FRα-expressing cells. ZW-191 mediates superior cellular internalization and payload delivery compared with other FRα-targeted antibodies applied in different ADCs[1]. ZW191 demonstrates strong FRα binding, superior tumor spheroid penetration, cellular internalization, and cytotoxic activity in FRα-expressing cancer cells[1][2].
References:
[1]. Lawn S, et al. Abstract 2641: ZW191, a novel FRa-targeting antibody drug conjugate bearing a topoisomerase 1 inhibitor payload. Cancer Research. 2023;83(7_Supplement):2641.
[2]. Lawn S, et al. Abstract 1862: ZW191 - a FRα-targeting antibody drug conjugate with strong preclinical activity across multiple FRα-expressing indications. Cancer Research. 2024;84(6_Supplement):1862.